( - )-1-(Benzofuran-2-yl)-2-propylaminopentane enhances locomotor activity in rats due to its ability to induce dopamine release

Seiichiro Shimazu, Kazue Takahata, Hiroshi Katsuki, Hiroko Tsunekawa, Akie Tanigawa, Fumio Yoneda, Joseph Knoll, Akinori Akaike

Research output: Contribution to journalArticle

25 Citations (Scopus)


"Catecholaminergic and serotoninergic activity enhancer" effects are newly found mechanisms of action of a class of compound that enhance impulse propagation-mediated release of catecholamines and serotonin in the brain. In the present study, ( - )-1-(benzofuran-2-yl)-2-propylaminopentane hydrochloride [( - )-BPAP HCl], a compound with selective and potent "catecholaminergic and serotoninergic activity enhancer" effects, was tested for its efficacy to potentiate locomotor activity in normal rats and to attenuate hypolocomotion in reserpine-treated rats. ( - )-BPAP HCl potentiated locomotor activity in non-habituated rats during a 2-h observation period dose-dependently (0.3-10 mg/kg). ( - )-BPAP HCl (1-3 mg/kg) was also effective to reverse reserpine-induced hypolocomotion. The effects of ( - )-BPAP HCl in normal and reserpine-treated rats were attenuated by the dopamine D1 receptor antagonist, R( + )-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SCH 23390), suggesting that the effects of ( - )-BPAP HCl were mediated by activation of the dopaminergic system. In addition, the administration of ( - )-BPAP HCl increased ipsilateral turning in unilaterally 6-hydroxydopamine-lesioned rats, implying presynaptic activation of nigrostriatal dopaminergic terminals by ( - )-BPAP HCl. Furthermore, although antiparkinsonian agents, such as apomorphine and amantadine, failed to improve reserpine-induced ptosis, ( - )-BPAP HCl significantly improved ptosis. These findings suggested that a "catecholaminergic and serotoninergic activity enhancer" compound, ( - )-BPAP, stimulates motor function in rats and improves motor deficits in animal models of Parkinson's disease due to its ability to induce dopamine release.

Original languageEnglish
Pages (from-to)181-189
Number of pages9
JournalEuropean Journal of Pharmacology
Issue number3
Publication statusPublished - Jun 15 2001



  • ( - )-Deprenyl
  • 6-Hydroxydopamine
  • Catecholaminergic and serotoninergic activity enhancer
  • Parkinson's disease
  • Reserpine
  • [( - )-BPAP HCl] ( - )-1-(benzofuran-2-yl)-2-propylaminopentane hydrochloride

ASJC Scopus subject areas

  • Pharmacology

Cite this